Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed/refractory follicular lymphoma who received ≥2 prior therapies: Updated results from a pivotal phase II study Meeting Abstract
| Authors: | Bartlett, N. L.; Sehn, L. H.; Matasar, M.; Schuster, S. J.; Assouline, S.; Giri, P.; Kuruvilla, J.; Canales, M.; Dietrich, S.; Fay, K.; Ku, M.; Nastoupil, L.; Wei, M. C.; Yin, S.; To, I.; Huang, H.; Min, J.; Bolen, C. R.; Penuel, E.; Budde, L. E. |
| Abstract Title: | Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed/refractory follicular lymphoma who received ≥2 prior therapies: Updated results from a pivotal phase II study |
| Meeting Title: | 11th Annual Meeting of the Society of Hematologic Oncology (SOHO 2023): Progress in Personalized Therapy |
| Keywords: | phase ii; follicular lymphoma; relapsed/refractory; bispecific antibody; ibcl; mosunetuzumab |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 23 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Sep 6-9 |
| Meeting Location: | Houston, TX |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2023-09-01 |
| Start Page: | S453 |
| Language: | English |
| ACCESSION: | WOS:001062479600494 |
| PROVIDER: | wos |
| DOI: | 10.1016/S2152-2650(23)01361-7 |
| Notes: | Meeting Abstract: IBCL-458 -- Source: Wos |
